# Sources — Frida Kahlo

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 2, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Museo Frida Kahlo. “Biography of Frida Kahlo” (Gerardo Ochoa Sandy; edited and updated by Ximena Jordan, 2020). Supports her birth on July 6, 1907, in the Blue House in Coyoacán; polio in 1913 at age six with a thinner, shorter right leg and outward-turned foot; the September 17, 1925 bus and streetcar collision and its injuries; beginning to paint in bed; lifelong chronic pain, many operations, and about 25 corsets; stopping her classes at La Esmeralda in 1944 because of limited mobility; her father’s epilepsy and death in 1941; her mother’s death in 1932; the 1950 hospitalization; the 1953 below-knee amputation; and her death at the Blue House on July 13, 1954, at 47. https://www.museofridakahlo.org.mx/wp/wp-content/uploads/2022/08/Biografias-Frida-Kahlo-ingles.pdf
2. Courtney CA, O’Hearn MA, Franck CC. “Frida Kahlo: Portrait of Chronic Pain.” *Physical Therapy* 2017;97(1):90–96. Abstract reviewed. Supports polio at six, a trolley car accident in her teens, lifelong chronic pain, numerous failed spinal surgeries, and limb amputation, and interprets her pain as chronic neuropathic pain with central sensitization (**R**). https://pubmed.ncbi.nlm.nih.gov/27562644/
3. Budrys V. “Neurological deficits in the life and works of Frida Kahlo.” *European Neurology* 2006;55(1):4–10. Abstract reviewed. Lists a congenital anomaly (spina bifida), poliomyelitis, spine injury, and neuropathic pain; the spina bifida proposal is graded **R** (possible). https://pubmed.ncbi.nlm.nih.gov/16432301/
4. HISTMED Master Roster v3. Internal project source. Its clinical claims were provisional and were not treated as independent corroboration.

## Clinical guidance

1. Dowell D, Ragan KR, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. *MMWR Recomm Rep* 2022;71(3):1–95. Nonopioid therapies first, regular reassessment of benefits and harms, naloxone, prescription drug monitoring program checks, urine drug testing, avoiding concurrent benzodiazepines, and gradual, collaborative tapering without abrupt discontinuation. The CDC page returned an access error, so the PubMed record is cited. https://pubmed.ncbi.nlm.nih.gov/36327391/
2. Qaseem A, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. *Ann Intern Med* 2017. Exercise, multidisciplinary rehabilitation, and cognitive behavioral therapy first; duloxetine among second-line drug options for chronic low back pain. https://www.acpjournals.org/doi/10.7326/M16-2367
3. VA/DoD Clinical Practice Guideline for the Diagnosis and Treatment of Low Back Pain (2022). https://www.healthquality.va.gov/guidelines/pain/lbp/
4. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), osteoarthritis and depression monographs. Pain and function at every visit; ALT with regular acetaminophen; radiographs only for diagnostic uncertainty; mood and coping screening; PHQ-9 every two to four weeks during active treatment. https://patrickrutledge.github.io/topthirty/
5. Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and the Centers for Disease Control and Prevention. Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention. *Ann Intern Med* 2016;164(6):425–434. Cited for the sick visit: no antibiotics for the common cold, no strep testing when cough and rhinorrhea point to a virus, and no chest radiograph unless pneumonia is suspected. https://pubmed.ncbi.nlm.nih.gov/26785402/
6. U.S. Preventive Services Task Force recommendations used at the adult preventive visit for a 37-year-old woman: Cervical Cancer: Screening (2018; HPV testing every five years from 30 to 65), https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening; Depression and Suicide Risk in Adults: Screening (2023), https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-depression-suicide-risk-adults; Anxiety Disorders in Adults: Screening (2023), https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening; Unhealthy Alcohol Use in Adolescents and Adults (2018), https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/unhealthy-alcohol-use-in-adolescents-and-adults-screening-and-behavioral-counseling-interventions; Unhealthy Drug Use: Screening (2020), https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/drug-use-illicit-screening; Tobacco Smoking Cessation in Adults (2021), https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions; Hypertension in Adults: Screening (2021), https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hypertension-in-adults-screening; HIV Infection: Screening (2019), https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/human-immunodeficiency-virus-hiv-infection-screening; Hepatitis C Virus Infection in Adolescents and Adults: Screening (2020), https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-c-screening; Intimate Partner Violence and Caregiver Abuse of Older or Vulnerable Adults: Screening (2025), https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/intimate-partner-violence-and-abuse-of-elderly-and-vulnerable-adults-screening; and Folic Acid Supplementation to Prevent Neural Tube Defects (2023; 0.4 to 0.8 mg daily for anyone who could become pregnant), https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication. The self-collected HPV sample is an FDA-approved collection option in health care settings; the 2018 USPSTF statement describes clinician-collected testing, so the clinical reviewer should confirm this choice against the current statement.
7. Conners EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023. *MMWR Recomm Rep* 2023;72(1). One-time triple-panel screening for adults 18 and older. https://pubmed.ncbi.nlm.nih.gov/36893044/
8. Medicare Preventive Services reference (Aether Forge, 2026): visit templates and documentation elements, used for the structure of the preventive note. https://patrickrutledge.github.io/preventative_services/ Vaccine items (hepatitis B for adults 19 to 59, HPV shared decision-making from 27 to 45, Tdap every ten years, seasonal influenza and COVID-19) follow the ACIP adult schedule; the CDC schedule page returned an access error and is not cited as a guideline record.

## Editorial resolutions

- **Roster correction.** The roster files Kahlo under “19th Century,” which does not fit a birth in 1907. The case uses “Early 20th Century.” Nationality is “Mexican.”
- **Index age.** The modern episode presents Kahlo at 37, her age in 1944, when limited mobility made her stop attending her classes at La Esmeralda. The index visit is September 17, 2026, the anniversary of the 1925 accident; the true-date frame places it on September 17, 1944. Past medical history and family history include only events before then. The 1950 hospitalization, the 1953 amputation, and her death remain in the historical timeline.
- **Modern diagnosis.** The documented injuries and chronic pain are **D**. The synthetic episode codes chronic pain due to trauma (G89.21), post-traumatic ankle osteoarthritis (M19.171), and long-term opioid therapy (Z79.891). The opioid history, doses, and taper are **S** and are not a statement about her historical treatment.
- **Contested cause of the leg weakness.** The contemporaneous diagnosis was polio, so the problem list records sequelae of poliomyelitis (B91) with verification provisional. The spina bifida proposal is **R** and stays off the active problem list.
- **Mood.** PHQ-9 scores stay below 10 with item 9 negative, so no depression diagnosis is coded and no structured safety assessment is required. The plan states that one will be done if the score reaches 10 or item 9 is positive.
- **Naloxone.** Naloxone 4 mg nasal spray was dispensed at the first visit, as the care plan records. The case schema now has a nasal route, so the spray is also on the medication list (MED-009, RxNorm 1725059, started at the first visit). Its structured frequency of 0.05 hours encodes the 2-to-3-minute repeat interval on the label, because the schema has no minute unit.
- **Added visits.** Two full encounter notes were added inside the fortnightly taper schedule. An unscheduled sick visit (ENC-005) falls on October 8, 2026, one week after the rehabilitation consultation and one week before the first dose reduction; the true-date frame places it on October 8, 1944. An adult preventive visit (ENC-006) falls on October 22, 2026, one week after the first dose reduction and one week before the six-week review; the true-date frame places it on October 22, 1944. Both are **S**, keep the index age of 37, and precede the 1950 hospitalization, so no documented event is contradicted. The preventive visit follows the influenza dose given at the four-week visit, so the vaccine is recorded as up to date rather than repeated.
- **Sick-visit illness.** A common cold (J06.9), resolved, was chosen because it interacts directly with her regimen without echoing any documented illness: she is already at the 3 g acetaminophen limit; a typical nighttime cold product combines acetaminophen, dextromethorphan (serotonergic with duloxetine 60 mg), and doxylamine (sedating with oxycodone); codeine cough syrups, and oral NSAIDs on top of duloxetine, are avoided; overlapping symptoms are distinguished from opioid withdrawal while the dose is unchanged; and ritonavir-boosted nirmatrelvir would raise oxycodone levels if she tested positive for COVID-19. The note allows the first reduction to move by a week if she were still unwell, as the taper plan permits; it went ahead on schedule.
- **Preventive-visit sensitivities.** Her miscarriages, the pelvic wound, and her marriage history stay unrecorded. Pregnancy intention and contraception were asked privately; she preferred not to discuss her reproductive history, and the note records only that the choice was respected. No statement or decision is attributed to her spouse, and the health care agent is not named. A self-collected HPV sample was chosen because lithotomy positioning aggravates her documented back and pelvic injuries; abdominal and pelvic scars are not described. The intimate partner violence screen is recorded as a routine negative screen with no further detail. AUDIT-C (1), no current tobacco use, and no nonprescribed drug use are modern-frame synthetic findings, not statements about her historical habits. PHQ-9 (5) and GAD-7 (4) stay below the thresholds that would require a structured safety assessment, between the PHQ-9 scores of 6 and 4 on either side. The fall-risk content (Timed Up and Go 14 seconds with a cane and shoe lift) reflects her documented right leg and spine disability.
- **Focused visits.** The three chronic pain follow-ups (two weeks, four weeks, and six weeks) are documented as focused visits. Chronic post-traumatic pain and long-term opioid therapy are not CMID conditions, so the protocol tables follow the CDC 2022 opioid guideline for taper monitoring (PEG at every visit, benefits and harms, the taper rate, withdrawal checks after each reduction, prescription drug monitoring program checks before each prescription, urine drug testing at least yearly, naloxone, avoiding sedatives, and an opioid use disorder assessment before tapering), the ACP and VA/DoD low back pain guidelines for rehabilitation and cognitive behavioral therapy, the CMID osteoarthritis monograph for the right ankle (joint examination, ALT on regular acetaminophen, no surveillance radiographs, oral NSAID labs not indicated with topical diclofenac), and the CMID depression monograph for the PHQ-9 cadence and the duloxetine tolerance checks. CMID names no function instrument for the ankle, so the PEG stands in. The two-week note is the primary-care visit on the day of the rehabilitation consultation; the consultation itself stays in the consult note. Synthetic findings introduced: brief nausea in the first days of duloxetine; easel standing times of about 15 minutes at two weeks and about 20 minutes at four weeks, leading to the recorded 25 to 30 minutes at six weeks; a prescription drug monitoring program check with the new prescription at the four-week visit, consistent with the social history; and examination findings (pupils, no ankle effusion, no withdrawal signs). The first taper step (60 to 52.5 MME a day, 12.5 percent) is slightly larger than the plan's 10 percent; the note explains that it is the smallest step possible with whole 5 mg tablets, and it was agreed with her. No protocol deviation was found: the PHQ-9 was repeated within four weeks, withdrawal was checked one and two weeks after the reduction, ALT was rechecked at six weeks, and no check fell due without a visit. The 25-hydroxyvitamin D recheck is recorded as due.
- **Consultation.** The physical medicine and rehabilitation referral and consultation (Theo Lindqvist, MD, a fictional consultant, on the day of the two-week visit) are **S**. The recommendations are what the record then shows: physical therapy twice weekly with graded exercise, core and hip strengthening, and aquatic therapy from that day; the shoe lift; the back brace kept for bad days (no skin breakdown under it at the preventive visit); duloxetine increased to 60 mg; cognitive behavioral therapy (started at four weeks); the easel goal of 30 minutes by six weeks; and a slow taper of about 10 percent starting at four weeks. Judgment calls: (1) no spinal imaging, nerve testing, injection, or ankle brace is recommended, because none appears later in the record; (2) the examination adds only a negative straight-leg raise, limited lumbar bending, and rising from a chair with her arms to Dr. Ortega's same-day findings, and describes no pelvic, abdominal, or scar findings; (3) the polio-affected leg is described with pacing advice only, with no post-polio diagnosis and no mention of the proposed spinal anomaly; (4) no leg-length measurement is invented; (5) her spouse is not mentioned and is given no statement, and her miscarriages, the pelvic wound, and her marriage history stay unrecorded.
- **Not used.** The museum biography mentions opioid use in her final year; this was not recorded, for safe-messaging reasons and because it postdates the index age. Her miscarriages, the details of the pelvic wound, and her marriage history are not recorded. Proposed fibromyalgia (Martínez-Lavín et al., 2000), post-polio syndrome (Nilsson, 2004), and cauda equina syndrome (Arslantas et al., 2024) have no reviewable abstract and are not cited. The year of *The Broken Column* was not verified from a logged source. Some popular sources give the polio year as 1914; the museum’s 1913 is used.
- Kahlo died in 1954, so the recent-death review rule does not apply. Ordinary clinical, provenance, and safe-messaging reviews remain required.
